AZD 0328

Drug Profile

AZD 0328

Alternative Names: AZD0328

Latest Information Update: 24 Feb 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antidementias; Quinuclidines
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Schizophrenia

Most Recent Events

  • 29 Jan 2009 Discontinued - Phase-II for Alzheimer's disease in European Union (PO)
  • 29 Jan 2009 Discontinued - Phase-II for Schizophrenia in USA (PO)
  • 07 Nov 2007 Pharmacodynamics data from preclinical trials presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) ,,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top